CLARENCE, N.Y.--(BUSINESS WIRE)--Greatbatch, Inc. (NYSE: GB) announced today that its subsidiary Precimed, S.A. (“Precimed”) has successfully completed the previously announced acquisition of DePuy’s Chaumont, France manufacturing facility. The Chaumont facility will continue to produce primary hip stems and shoulder implants for DePuy for the foreseeable future. This transaction, including a new 4-year supply agreement with DePuy, enhances Greatbatch’s and Precimed’s strategic relationship with one of the largest orthopedic companies in the world. The addition of this facility will align Precimed closer to its orthopedic OEM customers and further extends its offerings to a full range of orthopedic implants notably for the hip, shoulder and knee segments. The Chaumont facility has approximately 200 highly skilled employees with large-scale manufacturing expertise including machining of metals and plastics, engraving and laser etching, surface treatments, in house HA coatings capabilities and a Class 100,000 clean room with the ability to deliver a sterile packaged, fully labeled implant.
